Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18977228 | Ribociclib Tablet | December 2024 | June 2025 | Allow | 7 | 3 | 0 | No | No |
| 18829557 | NOVEL LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | September 2024 | April 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 18786785 | METHOD FOR HYPERTHERMIALLY TREATING A CANCER | July 2024 | October 2024 | Allow | 2 | 1 | 0 | No | No |
| 18632164 | PAINLESS NGF FOR FRACTURE REPAIR | April 2024 | May 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18603884 | TAMPER RESISTANT DOSAGE FORMS | March 2024 | July 2024 | Allow | 4 | 3 | 0 | No | No |
| 18599893 | HIGH STEROL-CONTAINING LIPID NANOPARTICLES | March 2024 | April 2025 | Allow | 13 | 2 | 0 | Yes | No |
| 18681556 | PREPARATION OF COMPOSITE GELS, POLYMER SCAFFOLDS, AGGREGATES AND FILMS COMPRISING SOLUBLE CROSS-LINKED CHITOSAN & USES THEREOF | February 2024 | May 2025 | Allow | 15 | 2 | 1 | Yes | No |
| 18431035 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | February 2024 | April 2025 | Allow | 14 | 1 | 0 | No | No |
| 18395521 | IMPLANTABLE POLYMER FOR BONE AND VASCULAR LESIONS | December 2023 | March 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18531424 | HETEROCYCLIC COMPOUNDS AND THEIR USES | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18512499 | CANCER TREATMENT METHOD FOR MAGNETIC HYPOTHERMIA CANCER TREATMENT | November 2023 | July 2024 | Allow | 8 | 1 | 0 | No | No |
| 18475755 | TAMPER RESISTANT DOSAGE FORMS | September 2023 | March 2024 | Allow | 5 | 1 | 0 | No | No |
| 18372560 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | September 2023 | December 2024 | Allow | 15 | 2 | 0 | No | No |
| 18459805 | POLYCAPROLACTONE-BASED FIBERS AND IMPLANTS INCLUDING SAME | September 2023 | November 2024 | Allow | 15 | 2 | 0 | Yes | No |
| 18450842 | METHOD FOR TREATING BREAST CANCER | August 2023 | November 2023 | Allow | 3 | 1 | 0 | No | No |
| 18337570 | COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL | June 2023 | August 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18205786 | TAMPER RESISTANT DOSAGE FORMS | June 2023 | December 2023 | Allow | 6 | 1 | 0 | Yes | No |
| 18204233 | Polyphosphate-Functionalized Inorganic Nanoparticles as Hemostatic Compositions and Methods of Use | May 2023 | November 2024 | Allow | 18 | 2 | 0 | Yes | No |
| 18143927 | TAMPER RESISTANT DOSAGE FORMS | May 2023 | September 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18298623 | TRANSDERMAL DELIVERY SYSTEM WITH A MICROPOROUS MEMBRANE HAVING SOLVENT-FILLEDPORES | April 2023 | May 2025 | Abandon | 25 | 3 | 0 | No | No |
| 18187904 | HIGH STEROL-CONTAINING LIPID NANOPARTICLES | March 2023 | December 2023 | Allow | 9 | 1 | 1 | Yes | No |
| 18184816 | IMPLANTABLE MEDICAL DEVICE WITH THERMOPLASTIC COMPOSITE BODY AND METHOD FOR FORMING THERMOPLASTIC COMPOSITE BODY | March 2023 | December 2023 | Allow | 9 | 2 | 0 | No | No |
| 18117315 | HYDRATION COMPOSITIONS | March 2023 | November 2024 | Allow | 21 | 1 | 0 | Yes | No |
| 18115854 | HEARTWORM MEDICAMENT | March 2023 | August 2023 | Allow | 6 | 1 | 0 | No | No |
| 18174674 | DRY POWDER FORMULATIONS FOR INHALATION | February 2023 | July 2024 | Allow | 16 | 2 | 0 | No | No |
| 18099953 | FORMULATIONS WITH COLLOIDAL SILVER | January 2023 | November 2024 | Allow | 22 | 2 | 0 | No | No |
| 18152965 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING A SILICONE POLYMER | January 2023 | July 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18095329 | SELF-LUBRICATING MEDICAL ARTICLES | January 2023 | January 2025 | Allow | 24 | 4 | 0 | No | No |
| 18148724 | Oral Care Compositions | December 2022 | March 2024 | Allow | 14 | 2 | 0 | Yes | No |
| 18146736 | Core-Shell Microcapsule with a Polyamine-Based Thermosetting Shell | December 2022 | May 2024 | Allow | 16 | 2 | 0 | Yes | No |
| 18083774 | SUSTAINED DELIVERY FORMULATIONS OF RISPERIDONE COMPOUND | December 2022 | November 2024 | Abandon | 23 | 2 | 0 | No | No |
| 18072772 | TREATMENT OF IMMUNE DISEASES BY ADMINISTRATION OF ANTIGEN-SPECIFIC FORMULATIONS | December 2022 | November 2023 | Allow | 11 | 1 | 0 | No | No |
| 17985757 | SYSTEMS AND METHODS FOR BLENDING SOLID-SHELL COSMETIC INGREDIENT CAPSULES AND BLENDABLE COSMETIC INGREDIENT CAPSULES | November 2022 | February 2024 | Allow | 15 | 1 | 0 | No | No |
| 17977902 | GELLING MULTIPARTICULATES | October 2022 | March 2024 | Allow | 17 | 1 | 0 | No | No |
| 17971025 | COMPOSITIONS AND METHODS FOR TREATMENT OF SYMPTOMS IN PARKINSON'S DISEASE PATIENTS | October 2022 | April 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 17954279 | Compositions for Inhibition of Insect Sensing | September 2022 | March 2025 | Abandon | 29 | 0 | 1 | No | No |
| 17934737 | COSMETIC COMPOSITIONS CAPABLE OF FORMING A MULTILAYER STRUCTURE AFTER APPLICATION TO A KERATINOUS MATERIAL | September 2022 | March 2023 | Allow | 5 | 1 | 0 | No | No |
| 17802984 | PROTEIN PRODUCT CAPABLE OF IMMOBILIZING TARGET AND BEING CLEARED AS REQUIRED | August 2022 | February 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 17892553 | TAMPER RESISTANT DOSAGE FORMS | August 2022 | December 2023 | Allow | 16 | 1 | 0 | Yes | No |
| 17818687 | POLYMER DERIVATIVES HAVING PARTICULAR ATOM ARRANGEMENTS | August 2022 | September 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17880175 | OCULAR HYDROGEL TYROSINE KINASE INHIBITOR IMPLANTS | August 2022 | August 2024 | Abandon | 24 | 1 | 0 | No | Yes |
| 17877542 | PREPARATION CONTAINING TETRACYCLIC COMPOUND AT HIGH DOSE | July 2022 | January 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17873968 | METHODS OF TREATING PATIENTS AT RISK FOR RENAL INJURY AND RENAL FAILURE | July 2022 | December 2023 | Allow | 17 | 1 | 0 | No | No |
| 17856682 | COMPOSITIONS AND RESULTING HARD CAPSULES COMPRISING HYDROPHILIC COLORING FOODSTUFF CONCENTRATES | July 2022 | December 2023 | Allow | 18 | 2 | 0 | No | No |
| 17810274 | SHAPE MEMORY ADHESIVES FOR APPAREL PRODUCTS | June 2022 | July 2023 | Allow | 12 | 2 | 1 | Yes | No |
| 17806033 | HETEROCYCLIC COMPOUNDS AND THEIR USES | June 2022 | September 2023 | Allow | 15 | 1 | 0 | No | No |
| 17805956 | Ribociclib Tablet | June 2022 | December 2023 | Allow | 18 | 1 | 0 | No | No |
| 17835739 | NANOPARTICLES FOR TARGETED NON-SURGICAL SPAYING AND NEUTERING | June 2022 | June 2025 | Allow | 37 | 3 | 1 | Yes | No |
| 17827504 | NATURAL COMPOSITION FOR USE IN GYNAECOLOGY | May 2022 | October 2023 | Allow | 17 | 2 | 0 | No | No |
| 17824425 | TOPICAL COMPOSITION AND METHOD OF USE | May 2022 | August 2024 | Allow | 27 | 1 | 1 | No | No |
| 17752813 | Scaffold for Regenerative Organization of Prosthetic Organ Tissue and Method | May 2022 | March 2024 | Abandon | 22 | 2 | 1 | Yes | No |
| 17721183 | METHOD OF TREATING EPILEPSY | April 2022 | June 2024 | Allow | 26 | 4 | 0 | Yes | No |
| 17712618 | Method and Apparatus for Treating Bone Fractures, and/or for Fortifying and/or Augmenting Bone, Including the Provision and Use of Composite Implants | April 2022 | October 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17699919 | HEMOSTATIC PASTE AND METHODS OF MAKING THEREOF | March 2022 | March 2023 | Allow | 12 | 2 | 0 | No | No |
| 17691299 | Capsule to support the body's defense against microplastics | March 2022 | January 2024 | Abandon | 23 | 1 | 0 | No | No |
| 17641056 | ONIUM SALT OF NITROGEN-CONTAINING HETEROARYL COMPOUND AND PEST CONTROL AGENT | March 2022 | June 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17686827 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | March 2022 | September 2023 | Allow | 18 | 4 | 0 | Yes | No |
| 17639932 | AQUEOUS CONDITIONER FORMULATION FOR THERMALLY STYLED HAIR | March 2022 | March 2025 | Allow | 36 | 1 | 0 | Yes | No |
| 17680646 | Polyurethane Based Medical Articles | February 2022 | July 2024 | Allow | 29 | 2 | 1 | No | No |
| 17631775 | METHOD FOR TREATING KERATIN MATERIAL, COMPRISING THE USE OF AN ORGANIC C1-C6-ALKOXY-SILANE AND AN AMINO ACID AND/OR AN AMINO ACID DERIVATIVE | January 2022 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17628424 | HAIR TREATMENT COMPOSITION, METHOD FOR OBTAINING SAME, USE OF THE COMPOSITION AND HAIR TREATMENT METHOD | January 2022 | April 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17628356 | HAIR CARE COMPOSITION | January 2022 | December 2024 | Allow | 35 | 1 | 0 | No | No |
| 17424622 | PHARMACEUTICAL COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | January 2022 | March 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17597290 | ANTIBACTERIAL ARTICLE COMPRISING A POLYMER MATRIX WITH ALIGNED NANOSCALE FLAKES OR PLATELETS | December 2021 | March 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17562690 | METHOD AND APPARATUS FOR TREATING BONE FRACTURES, AND/OR FOR FORTIFYING AND/OR AUGMENTING BONE, INCLUDING THE PROVISION AND USE OF COMPOSITE IMPLANTS, AND NOVEL COMPOSITE STRUCTURES WHICH MAY BE USED FOR MEDICAL AND NON-MEDICAL APPLICATIONS | December 2021 | June 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17623171 | TRANSDERMAL DRUG DELIVERY PATCH, DRUG DELIVERY SYSTEM AND DRUG DELIVERY METHOD | December 2021 | April 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17558763 | Multiple Unit Dosage Form Having A Therapeutic Agent In Combination With A Nutritional Supplement | December 2021 | September 2023 | Allow | 20 | 2 | 0 | No | No |
| 17619594 | RHODOSPIRILLUM RUBRUM CELLS THAT LOWER PLASMA CHOLESTEROL WHILE LEAVING OTHER SERUM PROTEIN LEVELS UNAFFECTED | December 2021 | March 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17553613 | SURFACE-REACTED CALCIUM CARBONATE IN FOOD | December 2021 | October 2023 | Allow | 22 | 1 | 0 | Yes | No |
| 17548849 | Pharmaceutical Combination for the Treatment of Cancer | December 2021 | October 2023 | Allow | 23 | 2 | 0 | Yes | No |
| 17596426 | FORMULATION FOR ODONTOLOGICAL AND DERMATOLOGICAL USE CONTAINING TRCHLOROACETATE SALTS AND HYDROXYACIDS | December 2021 | August 2024 | Allow | 32 | 1 | 0 | No | No |
| 17643046 | LIQUID COLLAGEN BIOINKS AND METHODS TO MAKE AND USE COLLAGEN STRUCTURES | December 2021 | July 2024 | Allow | 32 | 1 | 1 | No | No |
| 17614774 | COMPOSITION FOR FORMING COATING FILM | November 2021 | January 2025 | Allow | 38 | 1 | 0 | No | No |
| 17536674 | AQUEOUS COMPOSITION FOR LIVESTOCK ANIMALS | November 2021 | August 2023 | Abandon | 21 | 2 | 0 | No | No |
| 17529180 | PAINLESS NGF FOR FRACTURE REPAIR | November 2021 | April 2024 | Abandon | 29 | 1 | 0 | No | No |
| 17610242 | 2(1H)-PYRIDINONES AND THEIR USE TO TREAT INFLAMMATORY CONDITIONS | November 2021 | September 2024 | Allow | 35 | 1 | 0 | No | No |
| 17522358 | PETROLATUM SUBSTITUTION PREPARATION | November 2021 | December 2023 | Allow | 25 | 1 | 0 | No | No |
| 17522727 | HYDROGELS FORMED IN SITU AND COMPOSITION DESIGN FOR INTRAUTERINE USE | November 2021 | March 2025 | Allow | 40 | 2 | 1 | Yes | No |
| 17509037 | DRY POWDER FORMULATIONS FOR INHALATION | October 2021 | May 2023 | Abandon | 18 | 1 | 0 | No | No |
| 17503965 | PET SUPPLEMENTS CONTAINING A CANNABINOID | October 2021 | February 2024 | Abandon | 28 | 1 | 0 | No | No |
| 17499242 | ANTIMICROBIAL THIOURONIUM COPOLYMERS AND METHODS OF MAKING AND USING THE SAME | October 2021 | February 2024 | Allow | 28 | 1 | 1 | No | No |
| 17601120 | COLLOIDAL SILVER-BASED COMPOSITIONS AND METHODS OF USE THEREOF FOR PREVENTING AND CONTROLLING PLANT DISEASES | October 2021 | July 2024 | Allow | 34 | 0 | 0 | No | No |
| 17488650 | CANNABINOID CHEWING GUM WITH SUGAR ALCOHOLS | September 2021 | July 2023 | Allow | 22 | 2 | 0 | No | No |
| 17488492 | Alcohol Metabolism Acceleration Composition | September 2021 | December 2023 | Allow | 27 | 1 | 0 | Yes | No |
| 17599761 | TOPICAL COMPOSITION | September 2021 | February 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17483468 | TREATMENT OF COGNITIVE DYSFUNCTION WITH PYRROLOPYRIDINE-ANILINE COMPOUNDS | September 2021 | June 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17481263 | BIOMASS-BASED ENCAPSULATING MATERIAL FOR PROTECTION OF PROBIOTIC ACTIVITY AND AN ENCAPSULATING METHOD | September 2021 | December 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17593576 | DENTAL ADDITION SILICONE COMPOSITION | September 2021 | January 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17440703 | METHOD FOR DYEING KERATINOUS MATERIAL, COMPRISING THE USE OF AN ORGANOSILICON COMPOUND, AN EFFECT PIGMENT AND A FILM-FORMING POLYMER II | September 2021 | April 2025 | Allow | 43 | 2 | 1 | No | No |
| 17438886 | CAPSULE SHELL COMPRISING A CORE-SHELL POLYMER AND A CELLULOSE | September 2021 | October 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17436036 | METHOD FOR PREPARING AND USING HAIR TREATMENT AGENTS WITH ORGANIC C1-C6-ALKOXY-SILANES | September 2021 | December 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17463343 | SUBSTRATES FOR VAPORIZING AND DELIVERING AN AEROSOL | August 2021 | October 2022 | Allow | 13 | 3 | 1 | Yes | No |
| 17401542 | SCAFFOLDS FROM SELF-ASSEMBLING TETRAPEPTIDES SUPPORT 3D SPREADING, OSTEOGENIC DIFFERENTIATION AND ANGIOGENESIS OF MESENCHYMAL STEM CELLS | August 2021 | June 2024 | Allow | 34 | 1 | 1 | Yes | No |
| 17429045 | SURGICAL HYDROGEL | August 2021 | March 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17379351 | Mineral Coated Microparticles for Co-Delivery of Anti-Inflammatory Molecules with Nucleic Acids to Improve Gene Delivery Outcomes | July 2021 | June 2023 | Allow | 23 | 2 | 0 | Yes | No |
| 17290565 | PEPTIDE FOR PROMOTING MUCOUS MEMBRANE PERMEATION AND COMPOSITION CONTAINING SAME | July 2021 | April 2024 | Allow | 35 | 1 | 1 | Yes | No |
| 17372773 | Hydrogel Compositions | July 2021 | December 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17351758 | POROUS SILICATE/MAGNETIC FERRITE NANOCARRIER FOR COMBINATION ANTI-CANCER THERAPEUTIC AND ANTIOXIDANT DELIVERY | June 2021 | August 2023 | Allow | 26 | 1 | 1 | Yes | No |
| 17351190 | COMPARTMENTED HARD SHELL CAPSULE AND APPARATUS AND METHOD FOR FORMING, FILLING, AND ENCAPSULATING A COMPARTMENTED HARD SHELL CAPSULE | June 2021 | January 2024 | Abandon | 31 | 2 | 1 | Yes | No |
| 17350356 | Personalized Medicament Delivery Product | June 2021 | February 2024 | Abandon | 32 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner FUBARA, BLESSING M.
With a 43.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 26.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner FUBARA, BLESSING M works in Art Unit 1613 and has examined 1,154 patent applications in our dataset. With an allowance rate of 67.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.
Examiner FUBARA, BLESSING M's allowance rate of 67.2% places them in the 21% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by FUBARA, BLESSING M receive 2.21 office actions before reaching final disposition. This places the examiner in the 75% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by FUBARA, BLESSING M is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +35.9% benefit to allowance rate for applications examined by FUBARA, BLESSING M. This interview benefit is in the 86% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.5% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 40.5% of cases where such amendments are filed. This entry rate is in the 54% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 93.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 67% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 74.0% of appeals filed. This is in the 58% percentile among all examiners. Of these withdrawals, 53.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 61.5% are granted (fully or in part). This grant rate is in the 78% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 1.5% of allowed cases (in the 73% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.1% of allowed cases (in the 72% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.